Arcus Biosciences (NYSE:RCUS) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Arcus Biosciences (NYSE:RCUS) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on the stock. Wedbush upped their price target on shares of Arcus Biosciences from $43.00 to $49.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. began coverage on Arcus Biosciences in a research note on Wednesday, October 14th. They issued an “overweight” rating and a $41.00 price objective on the stock. Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a research report on Monday, August 10th. TD Cowen started coverage on Arcus Biosciences in a research report on Wednesday, September 16th. They set a “buy” rating for the company. Finally, Truist Financial increased their target price on Arcus Biosciences from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $39.64.

Arcus Biosciences Stock Down 4.2%

Shares of Arcus Biosciences stock opened at $18.54 on Friday. The stock has a market capitalization of $2.36 billion, a P/E ratio of -4.75 and a beta of 0.94. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The stock has a 50 day moving average price of $26.12 and a two-hundred day moving average price of $26.14. Arcus Biosciences has a 12-month low of $16.87 and a 12-month high of $31.74.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million for the quarter, compared to the consensus estimate of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The business’s revenue for the quarter was down 74.4% on a year-over-year basis. Equities analysts expect that Arcus Biosciences will post -3.55 earnings per share for the current year.

Insider Buying and Selling at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

Several institutional investors have recently bought and sold shares of RCUS. BlackRock Inc. acquired a new stake in shares of Arcus Biosciences in the 2nd quarter valued at $506,113,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Arcus Biosciences during the second quarter worth approximately $28,341,000. Bank of America Corp DE bought a new position in shares of Arcus Biosciences in the second quarter valued at approximately $25,759,000. Bank of New York Mellon Corp bought a new position in shares of Arcus Biosciences in the second quarter valued at approximately $16,741,000. Finally, Renaissance Technologies LLC raised its stake in shares of Arcus Biosciences by 1,198.8% in the first quarter. Renaissance Technologies LLC now owns 424,700 shares of the company’s stock valued at $9,174,000 after acquiring an additional 392,000 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Key Stories Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analyst support: Truist Financial and Wedbush both forecast strong price appreciation for RCUS, suggesting analysts see upside following the recent selloff. Truist Financial Forecasts Strong Price Appreciation for Arcus Biosciences Wedbush Forecasts Strong Price Appreciation for Arcus Biosciences
• Positive Sentiment: Promising casdatifan data: Arcus presented new ARC-20 data evaluating casdatifan across multiple lines of therapy in kidney cancer. The results may support the drug’s development and commercial potential, though investors are likely seeking additional details on efficacy and durability. Arcus Presents New Casdatifan Data
• Neutral Sentiment: Improved liquidity: Arcus estimates it held approximately $694 million in cash, cash equivalents and marketable securities as of September 30, 2026. Proceeds from the offering should further extend its funding runway for clinical development, but the benefit comes with shareholder dilution. Arcus Estimates Cash Position
• Negative Sentiment: Equity dilution: Arcus priced an underwritten public offering of 14.29 million shares at $17.50 per share, expected to raise $250 million before expenses. The discounted issuance increases the share count and was the primary catalyst for the stock’s decline. Arcus Prices $250 Million Offering
• Negative Sentiment: Investor litigation risk: Kuehn Law said it is investigating potential fiduciary-duty violations and alleged self-dealing by company officers and directors. The announcement does not establish wrongdoing, but it adds reputational and legal uncertainty. Kuehn Law Investigation

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.